Cost of illness of RSV infection in a middle-income tropical country.


Journal

The Turkish journal of pediatrics
ISSN: 2791-6421
Titre abrégé: Turk J Pediatr
Pays: Turkey
ID NLM: 0417505

Informations de publication

Date de publication:
2021
Historique:
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 29 9 2021
Statut: ppublish

Résumé

Despite the burden of disease of Respiratory syncytial virus (RSV) infection in children, there are important gaps in knowledge about the potential impact in terms of health as well as social and healthcare resources. The aim of this study was to describe the economic burden of RSV in the first two years of life in Colombia. We conducted a cost-of-illness study, taking a population prevalence-based approach. A decision tree model was constructed with a time horizon of two years. We defined the following outcomes: death, RSV infection with long term complications, RSV with acute complications, RSV without complications. Inpatient and outpatient costs were collected directly from medical invoices of patients who attended a tertiary referral hospital. The mean cost per patient with an RSV infection was US$ 178.35 CI 95% (30.7-541.67 US$). The total cost of RSV infection in children less than 2 years in Colombia was US $ 64 443 616 per year (CI 95% US$11 092 902 - US$195 722 867). In the probabilistic sensitivity analysis, the mean cost per patient with RSV infection was only sensitive to changes in the cost of recurrent wheezing, cost of outpatient visits and cost of hospitalizations. The infection by RSV in Colombia generates a high economic burden on the health system. Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models, and help guide prevention strategies against RSV.

Sections du résumé

BACKGROUND
Despite the burden of disease of Respiratory syncytial virus (RSV) infection in children, there are important gaps in knowledge about the potential impact in terms of health as well as social and healthcare resources. The aim of this study was to describe the economic burden of RSV in the first two years of life in Colombia.
METHODS
We conducted a cost-of-illness study, taking a population prevalence-based approach. A decision tree model was constructed with a time horizon of two years. We defined the following outcomes: death, RSV infection with long term complications, RSV with acute complications, RSV without complications. Inpatient and outpatient costs were collected directly from medical invoices of patients who attended a tertiary referral hospital.
RESULTS
The mean cost per patient with an RSV infection was US$ 178.35 CI 95% (30.7-541.67 US$). The total cost of RSV infection in children less than 2 years in Colombia was US $ 64 443 616 per year (CI 95% US$11 092 902 - US$195 722 867). In the probabilistic sensitivity analysis, the mean cost per patient with RSV infection was only sensitive to changes in the cost of recurrent wheezing, cost of outpatient visits and cost of hospitalizations.
CONCLUSION
The infection by RSV in Colombia generates a high economic burden on the health system. Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models, and help guide prevention strategies against RSV.

Identifiants

pubmed: 34449150
pii: 2334
doi: 10.24953/turkjped.2021.04.015
doi:
pii:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

673-682

Auteurs

Jefferson Antonio Buendía (JA)

Grupo de Investigación en Farmacología y Toxicología (INFARTO). Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Carrera, Medellín, Colombia.

Diana Guerrero Patino (DG)

Grupo de Investigación en Farmacología y Toxicología (INFARTO). Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Carrera, Medellín, Colombia.

Denis Sinisterra (D)

Grupo de Investigación en Farmacología y Toxicología (INFARTO). Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad de Antioquia, Carrera, Medellín, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH